BNP (1-32), human |
| Catalog No.GP10071 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 114471-18-0
Sample solution is provided at 25 µL, 10mM.
GlpBio Products Cited In Reputable Papers
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Product Documents
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Protocol
| Cell experiment: [1] | |
|
Cell lines |
Normal adult canine ventricular fibroblasts |
|
Preparation method |
The solubility of this peptide in sterile water is >10 mM. Stock solution should be splited and stored at -80°C for several months. |
|
Reaction Conditions |
1 μM, 5 min |
|
Applications |
BNP (1 μM) significantly increased the intracellular cGMP, whereas lower concentrations did not alter the cGMP. At this concentration, BNP elevated cGMP levels with a maximal effect at 5 minutes. BNP (1 μM) significantly inhibited the [3H]proline incorporation into the cells by 29%. |
| Animal experiment: [2] | |
|
Animal models |
Adult Japanese white rabbits |
|
Dosage form |
Injected through the sclera into the vitreous cavity, 100 μM, 4 hours |
|
Applications |
At 100 μM, BNP treatment induced a significant decrease in IOP compared with vehicle-treated eyes. In particular, there were statistically significant differences at 4 and 6 hours. In addition, BNP treatment at 10 μM caused a significant decrease in IOP compared to the vehicle-treated eyes, but only at 6 hours after the injection. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Tsuruda T, Boerrigter G, Huntley B K, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circulation research, 2002, 91(12): 1127-1134. [2] Takashima Y, Taniguchi T, Yoshida M, et al. Ocular hypotensive mechanism of intravitreally injected brain natriuretic peptide in rabbit. Investigative ophthalmology & visual science, 1996, 37(13): 2671-2677. | |
| Cas No. | 114471-18-0 | SDF | |
| Formula | C143H244N50O42S4 | M.Wt | 3464.04 |
| Solubility | ≥206.6mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Complete Stock Solution Preparation Table
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2887 mL | 1.4434 mL | 2.8868 mL |
| 5 mM | 0.0577 mL | 0.2887 mL | 0.5774 mL |
| 10 mM | 0.0289 mL | 0.1443 mL | 0.2887 mL |
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Related Products
- GP10010 COG 133
- GP10089 Platelet Membrane Glycoprotein IIB Peptide (296-306)
- GP10016 Lamin fragment
- GP10113 Adrenomedullin (1-12), human
- GP10106 Parathyroid Hormone (1-34), bovine
- GP10050 type I hair keratin fragment [Homo sapiens]/[Ovis aries]/[Rattus norvegicus]
- GP10014 parathyroid hormone (7-34) [Homo sapiens]/[Macaca fascicularis]
- GP10077 Angiotensin (1-7)
- GP10047 HBcAg [Hepatitis B virus] (18-27)
- GP10017 [Ser25] Protein Kinase C (19-31)
- GP10060 a-MSH, amide
- GP10088 Luteinizing hormone releasing hormone human acetate salt (LHRH)
- GP10040 heparin cofactor II precursor (SERPIND1) fragment [Homo sapiens]
- GP10037 Large T antigen - rhesus polyomavirus 560-568
- GP10145 signal transducer and activator of transcription 6 fragment
- GP10144 Angiotensin 1/2 (1-7) amide
- GP10078 Papain Inhibitor
리뷰
Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *